NA
INTS icon

NewEdge Advisors’s Intensity Therapeutics INTS Stock Holding History

NewEdge Advisors’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.71K Hold
1,148
– – ﹤0.01% 3739
2026
Q1 		$6.75K Buy
1,148
+148
+15% +$1.21K ﹤0.01% 3498
2025
Q4 		$10.3K Buy
+1,000
New +$10.1K ﹤0.01% 3466

Other funds holding INTS

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors's INTS Position: Q2 2026 in Review

NewEdge Advisors held its Intensity Therapeutics (INTS) position steady in Q2 2026 at 1,148 shares worth $4.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

NewEdge Advisors first reported a position in INTS in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.3K in Q4 2025. 17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • NewEdge Advisors held 1,148 shares of Intensity Therapeutics worth $4.71K as of Q2 2026.
  • NewEdge Advisors left its Intensity Therapeutics share count unchanged in Q2 2026.
  • Intensity Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3739 holding.
  • NewEdge Advisors first reported a position in Intensity Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • NewEdge Advisors's Intensity Therapeutics position peaked at $10.3K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.